Zhongping Xu1, Wei Yang, Nancy Steward, Stuart C Sweet, Lara Danziger-Isakov, Peter S Heeger, Thalachallour Mohanakumar. 1. 1 Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ. 2 Department of Genetics, Washington University School of Medicine, St. Louis, MO. 3 Department of Pediatrics, Washington University School of Medicine, St. Louis, MO. 4 Cincinnati Children's Hospital Medical Center, Cincinnati, OH. 5 Department of Medicine, Recanati Miller Transplant Institute and Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Abstract
BACKGROUND: Acute rejection (AR) and development of chronic rejection, bronchiolitis obliterans syndrome (BOS) remain major limiting factors for lung transplantation (LTx). This retrospective study is to identify differentially expressed circulating microRNAs (miRNAs) that associate with development of AR and BOS in pediatric lung transplant recipients (LTxR). METHODS: We determined the circulating levels of 7 selected candidate miRNAs in 14 LTxR with AR, 7 with BOS, and compared them against 13 stable pediatric LTxR at 1, 6, and 12 months after LTx. In addition, 6 AR, 7 BOS, and 8 stable pediatric LTxR, 16 AR, 17 BOS, and 16 stable adult LTxR were included for validation. RESULTS: MiR-10a, -195, -133b were significantly lower in AR and miR-144, -142-5p, -155 were higher in AR compared to stable (P < 0.05). In addition, circulating levels of miR-134, -10a, -195, -133b were significantly lower and miR-144, -142-5p, -155 were higher (P < 0.05) with development of BOS. The receiver-operating characteristic demonstrated that miR-142-5p, miR-155, and miR-195 strongly discriminated patients with AR from stable LTxR (P < 0.001 for all comparisons): miR-142-5p (area under the curve [AUC], 0.854), miR-155 (AUC, 0.876), and miR-195 (AUC, 0.872). Further, miR-10a, miR-142-5p, miR-144, and miR-155 strongly discriminated BOS from stable LTxR (P < 0.001 for all comparisons). CONCLUSIONS: We demonstrated that differential expression of circulating miRNAs occurs in LTxR with AR and BOS, suggesting that they can provide not only important clues to pathogenesis but also may serve as potential noninvasive biomarkers for AR and BOS after pediatric LTx.
BACKGROUND: Acute rejection (AR) and development of chronic rejection, bronchiolitis obliterans syndrome (BOS) remain major limiting factors for lung transplantation (LTx). This retrospective study is to identify differentially expressed circulating microRNAs (miRNAs) that associate with development of AR and BOS in pediatric lung transplant recipients (LTxR). METHODS: We determined the circulating levels of 7 selected candidate miRNAs in 14 LTxR with AR, 7 with BOS, and compared them against 13 stable pediatric LTxR at 1, 6, and 12 months after LTx. In addition, 6 AR, 7 BOS, and 8 stable pediatric LTxR, 16 AR, 17 BOS, and 16 stable adult LTxR were included for validation. RESULTS:MiR-10a, -195, -133b were significantly lower in AR and miR-144, -142-5p, -155 were higher in AR compared to stable (P < 0.05). In addition, circulating levels of miR-134, -10a, -195, -133b were significantly lower and miR-144, -142-5p, -155 were higher (P < 0.05) with development of BOS. The receiver-operating characteristic demonstrated that miR-142-5p, miR-155, and miR-195 strongly discriminated patients with AR from stable LTxR (P < 0.001 for all comparisons): miR-142-5p (area under the curve [AUC], 0.854), miR-155 (AUC, 0.876), and miR-195 (AUC, 0.872). Further, miR-10a, miR-142-5p, miR-144, and miR-155 strongly discriminated BOS from stable LTxR (P < 0.001 for all comparisons). CONCLUSIONS: We demonstrated that differential expression of circulating miRNAs occurs in LTxR with AR and BOS, suggesting that they can provide not only important clues to pathogenesis but also may serve as potential noninvasive biomarkers for AR and BOS after pediatric LTx.
Authors: Waqar R R Farid; Qiuwei Pan; Adriaan J P van der Meer; Petra E de Ruiter; Vedashree Ramakrishnaiah; Jeroen de Jonge; Jaap Kwekkeboom; Harry L A Janssen; Herold J Metselaar; Hugo W Tilanus; Geert Kazemier; Luc J W van der Laan Journal: Liver Transpl Date: 2012-03 Impact factor: 5.799
Authors: Richard Danger; Annaïck Pallier; Magali Giral; Marc Martínez-Llordella; Juan José Lozano; Nicolas Degauque; Alberto Sanchez-Fueyo; Jean-Paul Soulillou; Sophie Brouard Journal: J Am Soc Nephrol Date: 2012-01-26 Impact factor: 10.121
Authors: Jan D Haas; Kiran Nistala; Franziska Petermann; Namita Saran; Vijaykumar Chennupati; Susanne Schmitz; Thomas Korn; Lucy R Wedderburn; Reinhold Förster; Andreas Krueger; Immo Prinz Journal: PLoS One Date: 2011-05-26 Impact factor: 3.240
Authors: Jun Cai; Ricardo Gehrau; Zhenxiao Tu; Victoria Leroy; Gang Su; Junyi Shang; Valeria R Mas; Amir Emtiazjoo; Andres Pelaez; Carl Atkinson; Tiago Machuca; Gilbert R Upchurch; Ashish K Sharma Journal: J Heart Lung Transplant Date: 2020-09-28 Impact factor: 10.247
Authors: Monal Sharma; Ranjithkumar Ravichandran; Sandhya Bansal; Ross M Bremner; Michael A Smith; T Mohanakumar Journal: Hum Immunol Date: 2018-06-15 Impact factor: 2.850
Authors: Ruth P Duecker; Ines De Mir Messa; Silvija-Pera Jerkic; Annalena Kochems; Gabriele Gottwald; Antonio Moreno-Galdó; Martin Rosewich; Lucia Gronau; Stefan Zielen; Andreas Geburtig-Chiocchetti; Hermann Kreyenberg; Ralf Schubert Journal: Clin Transl Immunology Date: 2022-02-21